Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Acquired by CKW Financial Group

CKW Financial Group increased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 11.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 955 shares of the medical equipment provider’s stock after buying an additional 100 shares during the period. CKW Financial Group’s holdings in Zimmer Biomet were worth $101,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of ZBH. Equity Investment Corp acquired a new position in shares of Zimmer Biomet in the third quarter valued at approximately $70,104,000. Hotchkis & Wiley Capital Management LLC increased its position in Zimmer Biomet by 49.1% during the third quarter. Hotchkis & Wiley Capital Management LLC now owns 1,752,298 shares of the medical equipment provider’s stock worth $189,161,000 after purchasing an additional 577,320 shares during the last quarter. Van ECK Associates Corp increased its position in Zimmer Biomet by 12.4% during the third quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider’s stock worth $391,239,000 after purchasing an additional 411,163 shares during the last quarter. Thompson Siegel & Walmsley LLC acquired a new position in Zimmer Biomet during the third quarter worth approximately $41,588,000. Finally, FMR LLC increased its position in Zimmer Biomet by 27.6% during the third quarter. FMR LLC now owns 750,336 shares of the medical equipment provider’s stock worth $80,999,000 after purchasing an additional 162,384 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Trading Down 0.2 %

NYSE ZBH opened at $110.78 on Monday. Zimmer Biomet Holdings, Inc. has a 12 month low of $100.67 and a 12 month high of $133.90. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70. The company has a market capitalization of $22.05 billion, a price-to-earnings ratio of 21.06, a price-to-earnings-growth ratio of 1.88 and a beta of 1.02. The company’s fifty day moving average price is $107.86 and its two-hundred day moving average price is $108.14.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting analysts’ consensus estimates of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The firm had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.80 billion. During the same period in the prior year, the firm posted $1.65 EPS. The firm’s revenue was up 4.1% compared to the same quarter last year. As a group, research analysts predict that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Monday, December 30th will be given a $0.24 dividend. The ex-dividend date is Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.87%. Zimmer Biomet’s payout ratio is currently 18.25%.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Barclays dropped their price target on shares of Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating for the company in a research report on Thursday, December 12th. Stifel Nicolaus upped their price target on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research report on Thursday. Wells Fargo & Company upped their price target on shares of Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. BTIG Research dropped their price target on shares of Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating for the company in a research report on Thursday, October 3rd. Finally, Oppenheimer dropped their price objective on shares of Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a research report on Tuesday, October 15th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $124.11.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.